Here, we provided a promising avenue for the exploration of targeted therapies that modulate the NFKB-miR-29b/c axis to attenuate UPR-GS activation and mitigate tumor aggressiveness (Figure 7), though in vitro and in vivo validation of our findings are warranted. The gene discussed is NFKB1; the disease is neoplasm.